Refractory heart failure: A therapeutic approach

Journal of Intensive Care Medicine

Volumn 11, Issue 3, 1996, Pages 121-148

  De Marco, Teresa ^a   Chatterjee, Kanu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENOXIMONE; FLOSEQUINAN; HYDRALAZINE; IBOPAMINE; MILRINONE; NITRATE; PIPERANOMETOZINE; PLACEBO; XAMOTEROL;

ENZYME INHIBITION; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMIC MONITORING; HUMAN; INOTROPISM; INTENSIVE CARE UNIT; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REFRACTORY PERIOD; RESUSCITATION; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0029924684     PISSN: 08850666     EISSN: None     Source Type: Journal    
DOI: 10.1177/088506669601100301     Document Type: Review

References (356)

1. Deedwania PC. Prevalence and prognosis of heart failure. In: Deedwania PC, ed. Cardiology clinics. Congestive heart failure: state of the art. Philadelphia: W.B. Saunders, 1994:1-8
2. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988;62:25A-30A
3. Kannel WB. Epidemiological aspects of heart failure. Cardiol Clin 1989;7:1-9
4. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990;65:903-908
5. Grodman AH, Deedwania PC. Predictors of mortality in patients with heart failure. In: Deedwania PC, ed. Cardiology clinics. Congestive heart failure: state of the art. Philadelphia: W.B. Saunders, 1994:25-36
6. Middlekauff HR, Stevenson WC, Stevenson LW, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993;21:110-116
7. Mancini DM, Wong WL, Simson MH. Prognostic value of an abnormal signal-averaged electro-cardiogram in patients with non-ischemic congestive cardiomyopathy. Circulation 1993;87:1083-1092
8. Pinamonti B, Di Lenarda A, Sinagra G, et al. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by doppler echocardiography: clinical echocardiographic and hemodynamic correlations and prognostic implications. J Am Coll Cardiol 1993;22:808-815
9. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985; 72:681-685
10. Parmley WW. Pathophysiology and current therapy of congestive heart failure. J Am Coll Cardiol 1989;13:771-785
11. Cody RJ, Pickworth KK. Approaches to diuretic therapy and electrolyte imbalance in congestive heart failure. In: Deedwania PC, ed. Cardiology clinics. Congestive heart failure: state of the art. Philadelphia: W.B. Saunders, 1994:37-50
12. Cody RJ, Covit AB, Shaer GL, et al. Sodium and water balance in chronic congestive heart failure. J Clin Invest 1986;77:1441-1452
13. Mujais SK, Nora NA, Levin ML. Principles and clinical uses of diuretic therapy. Prog Cardiovasc Dis 1992;35:221-245
14. Reis SE, Baughman KL. Treatment of severe congestive heart failure. Choices Cardiol 1994;8:102-105
15. Elkayam V. Nitrates in heart failure. In: Deedwania PC, ed. Cardiology clinics. Congestive heart failure: state of the art. Philadelphia: W.B. Saunders, 1994:73-86
16. Greenberg B. Role of vasodilator therapy in congestive heart failure: effects on mortality. In: Deedwania PC, ed. Cardiology clinics. Congestive heart failure: state of the art. Philadelphia: W.B. Saunders, 1994:87-100
17. Pitt B. Blockade of the renin-angiotensin system: effect on mortality in patients with left ventricular systolic dysfunction. In: Deedwania PC, ed. Cardiology clinics. Congestive heart failure: state of the art. Philadelphia: W.B. Saunders, 1994:101-114
18. Cohn JN, Archibald DG, Ziesche S, et al. Effects of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med 1986;314:1547-1552
19. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-1435
20. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
21. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hychalazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310
22. Barabino A, Galbariggi G, Pizzorni C, Lotti G. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology 1991;78:243-256
23. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691
24. Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting enzyme inhibition. Lancet 1991; 337:872-876
25. Young JB. Do digitalis glycosides still have a role in congestive heart failure? In: Deedwania PC, ed. Cardiology clinics. Congestive heart failure: state of the art. Philadelphia: W.B. Saunders, 1994:51-62
26. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989;13:134-142
27. Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 1989;80:65-77
28. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-544
29. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-683
30. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993;22:955-962
31. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors (RADIANCE). N Engl J Med 1993;329:1-7
32. Van Veldhuisen DJ, Man in 'T Veld AJ, Dunselman PHJM, et al. Double-blind placebo controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993;22:1564-1573
33. Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systemic overview and meta-analysis. Am J Med 1990;88:279-286
34. Minotti JR, Dudley G. Pathophysiology of exercise intolerance and the role of exercise training in congestive heart failure. Curr Opin Cardiol 1993;8:397-403
35. Mancini DM. Mechanisms of dyspnea in patients with heart failure. Cardiology 1994;18-51
36. Packer M. The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254
37. Chatterjee K, Viquerat CE, Daly P. Neurohormonal abnormalities in heart failure. Heart Fail 1985;1:69-83
38. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-888
39. Cabrol C, Gandjbakheh I, Pavie A, et al. Current problems in cardiac transplantation. Biomed Pharmacother 1989; 43:87-92
40. Stevenson LW, Miller L. Cardiac transplantation as therapy for heart failure. Curr Prob Cardiol 1991;164:219-305
41. Stevenson LW. Tailored therapy before transplantation for treatment of advanced heart failure: effective use of vasodilators and diuretics. J Heart Lung Transplant 1991;10:468-476
42. De Marco T, Keith F. Bridge to cardiac transplantation. In: Parmley WW, Chatterjee K, eds. Cardiology, vol 3. Philadelphia: J.B. Lippincott, 1994:1-21
43. Chatterjee K, De Marco T. Treatment of symptomatic heart failure. In: Dhalla NS, Beamish RE, Takeda N, Nagono M, eds. The failing heart. New York: Raven Press, Ltd, 1995:337-353
44. Weber KT, Brilla CG. Pathologic hypertrophy and cardiac interstitium. Fibrosis and the renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865
45. Lamas GA, Pfeffer MA. Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition. Am Heart J 1991;121:1194-1202
46. De Marco T, Chatterjee K, Rouleau JL, Parmley WW. Abnormal coronary hemodynamics and myocardial energetics in patients with chronic heart failure caused by ischemic heart disease and dilated cardiomyopathy. Am Heart J 1988; 115:809-815
47. Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990;81:772-779
48. Rockman HA, Juneau C, Chatterjee K, Rouleau JL. Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1989;64:1344-1348
49. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823
50. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205-211
51. Mauro VF, Mauro LS. Use of intermittent dobutamine infusion in congestive heart failure. Drug Intell Clin Pharm 1986;20:919-924
52. Bendersky R, Chatterjee K, Parmley WW, et al. Dobutamine in chronic ischemic heart failure: alterations in left ventricular function and coronary hemodynamics. Am J Cardiol 1981;48:554-558
53. Beregovich J, Bianchi C, Rubler S, et al. Dose-related hemodynamic and renal effects of dopamine in congestive heart failure. Am Heart J 1974;87:550-557
54. Parker M, Carlon GC, Isaacs M, et al. Dopamine administration in oliguria and oliguric renal failure. Crit Care Med 1981;9:630-632
55. Goldberg LI, Hsieh Y-Y, Resnekov L. Lower catecholamines for treatment of heart failure and shock: An update on dopamine and a first look at dobutamine. Prog Cardiovas Dis 1977;19:327-340
56. Crexells C, Bourassa MG, Biron P. Effects of dopamine on myocardial metabolism in patients with ischemic heart disease. Cardiovasc Res 1973;7:438-445
57. Henwood JM, Todd PA. Ibopamine: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1988;36:11-31
58. 2-adrenoreceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991;43:203-242
59. Itoh H. Clinical pharmacology of ibopamine. Am J Med 1991;90(suppl 5B):36S-42S
60. Francis GS. Inotropic agents in the management of heart failure. In: Cohn JN, ed. Drug treatment of heart failure. Secaucus, NJ: Advanced Therapeutics Communications International, 1988:179-197
61. Milkulic E, Cohn JN, Francisca JA. Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure. Circulation 1977;56:528-533
62. Leier CV, Wehel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 1977;56:468-472
63. Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980;100:622-630
64. Hodgson JM, Aja M, Sarkin RP. Intermittent ambulatory dobutamine infusions for patients awaiting cardiac transplantation. Am J Cardiol 1984;53:375-376
65. Berger M, McSherry CK. Outpatient dobutamine infusion using a totally implantable infusion pump for refractory congestive heart failure. Chest 1985;88:295-296
66. David S, Zaks JM. Arrhythmias associated with intermittent outpatient dobutamine infusion. Angiology 1986;57:86-91
67. Krell MJ, Kline EM, Bates ER, et al. Intermittent ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986;112:787-791
68. Collins JA, Skidmore MA, Melvin DB, Engel PJ. Home intravenous dobutamine therapy in patients awaiting heart transplantation. J Heart Transplant 1990;9:205-208
69. Miller LW. Outpatient dobutamine for refractory congestive heart failure: advantages, techniques, and results. J Heart Lung Transplant 1991;10:482-487
70. Leier CV, Huss P, Lewis RP, Unverferth DV. Drug-induced conditioning in congestive heart failure. Circulation 1982; 65:1382-1387
71. Applefield MM, Newman KA, Sutton FJ, et al. Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients. Am Heart J 1987;114:589-595
72. Dies F. Intermittent dobutamine in ambulatory patients with chronic cardiac failure. Br J Clin Pract 1986;45(suppl):37-40
73. Brogden RN, Speight TM, Avery GS. Levodopa: a review of its pharmacological properties and therapeutic uses with particular reference to Parkinsonism. Drugs 1971;2: 262-400
74. Rajfer SI, Anton AH, Rossen JD, Goldberg LI. Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. N Engl J Med 1984;310:1357-1362
75. De Marco T, Daly PA, Chatterjee K. Systemic and coronary hemodynamic and neurohormonal effects of levodopa in chronic congestive heart failure. Am J Cardiol 1988;62: 1228-1233
76. Chatterjee K. Newer oral inotropic agents: phosphodiesterase inhibitors. Crit Care Med 1990;18:S34-S38
77. Mancini D, LeJemtel T, Sonnenblick E. Intravenous use of amrinone for the treatment of the failing heart. Am J Cardiol 1985;56:8B-15B
78. Chatterjee K, Wolfe CL, De Marco T. Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful? In: Deedwania PC, ed. Cardiology clinics. Congestive heart failure: state of the art. Philadelphia: W.B. Saunders, 1994:63-72
79. Katz SD, Kubo SH, Jessup M, et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 1992; 123:92-103
80. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. Circulation 1992;85:942-949
81. Ruegg JC. Effects of new inotropic agents on calcium sensitivity of contractile proteins. Circulation 1986;73(suppl III):-III-78-III-83
82. Bohm M, Morano I, Pieske B, et al. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 1991;68:689-701
83. Hagemeijer F, Brand HJ, van Mechelen R. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989;63:571-576
84. Baim DS. Effects of amrinone on myocardial energetics in severe congestive heart failure. Am J Cardiol 1985;56: 16B-18B
85. Rutman MI, LeJemtel TH, Sonnenblick EH. Newer cardiotonic agents: implications for patients with heart failure and ischemic heart disease. J Cardiothorac Anesth 1987;1:59-70
86. Kaplan JA. Amrinone: contemporary management of the low cardiac output syndrome. J Cardiothorac Anesth 1989; 3(suppl 2):1-60
87. Kubo SH, Cody RJ, Chatterjee K, et al. Acute dose range study of milrinone in congestive heart failure. Am J Cardiol 1985;55:726-730
88. Kereiakes DJ, Viquerat C, Lanzer P, et al. Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failure. Am Heart J 1984;108:1278-1284
89. Baim DS, McDowell AV, Cherniles J, et al. Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N Engl J Med 1983; 309:748-756
90. Wynne J, Malacoff RF, Benotti JR, et al. Oral amrinone in refractory congestive heart failure. Am J Cardiol 1980; 45:1245-1249
91. Benotti JR, Grossman W, Braunwald G, et al. Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med 1978;299:1373-1377
92. LeJemtel TH, Keung E, Ribner HS, et al. Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. Am J Cardiol 1980;45:123-129
93. Axelrod RJ, De Marco T, Dae M, et al. Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure. J Am Coll Cardiol 1987;9:1124-1130
94. Daly PA, Chatterjee K, Viquerat CE, et al. R013-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure. Am J Cardiol 1985;55: 1539-1544
95. Eichhorn EJ, Konstam MA, Weiland DS, et al. Differential effects of milrinone and dobutamine on right ventricular preload, afterload, and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1987;60:1329-1333
96. Monrad ES, McKay RG, Baim DS, et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 1984;70:1030-1037
97. Viquerat CE, Kereiakes D, Morris DL, et al. Alterations in left ventricular function, coronary hemodynamics, and myocardial catecholamine balance with MDL 17,043: a new inotropic vasodilator agent in patients with severe heart failure. J Am Coll Cardiol 1985;5:326-332
98. Monrad ES, Baim DS, Smith HS, et al. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 1985; 71:972-979
99. LeJemtel TH, Maskin CS, Mancini D, et al. Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. Circulation 1985;72:364-369
100. Leier CV, Meiler SEL, Matthews S, Unverferth DV. A preliminary report of the effects of orally administered enoximone on regional hemodynamics in congestive heart failure. Am J Cardiol 1987;60:27C-30C
101. Clifton G, McMahon G, Ryan J, et al. The effects of enoximone on renal function in patients with congestive heart failure. Clin Pharmacol Ther 1989;45:85-91
102. Gage J, Rutman H, Lucido D, LeJemtel TH. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 1986;74:367-373
103. Watson DM, Sherry KM, Weston GA. Milrinone, a bridge to transplantation. Anaesthesia 1991;46:285-287
104. Moore J. Intravenous amrinone therapy at home for the patient with chronic congestive heart failure. Focus Crit Care 1988;15:32-37
105. Roth SNL, Moe G. Intermittent intravenous amrinone infusion: a potentially cost-effective mode of treatment of patients with refractory heart failure. Can J Cardiol 1993; 9:231-237
106. Taira N, Endoh M, Iijima T, et al. Mode and mechanism of actionof3.4-dihydro-6-[4(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), a novel positive inotropic drug on the dog heart. Arzneimittelforschung 1984;34:347-355
107. 2+ channels in ventricular myocytes of guinea pig. J Cardiovasc Pharmacol 1989;13:812-819
108. Iijima T, Taira N. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of guinea pig heart. J Pharmacol Exp Ther 1987;240:657-662
109. Lathrop DA, Schwartz A. Evidence for possible increase in sodium channel open time and involvement of Na/Ca exchange by a new positive inotropic drug: OPC-8212. Eur J Pharmacol 1985;117:391-392
110. Feldman AM, Becker LC, LLewllyn MP, Baughman KL. Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure. Am Heart J 1988;116:771-777
111. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-155
112. Yates DB. Pharmacology of flosequinan. Am Heart J 1991;121:974-983
113. Packer M, Narahara KA, Elkayam U, et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. J Am Coll Cardiol 1993;22:65-72
114. Lang D, Lewis MJ. The effects of flosequinan on endothelin-1-induced changes in inositol 1,4,5-triphosphate levels and protein kinase C activity in rat aorta. Eur J Pharmacol 1992;226:259-264
115. Cowley AJ, Wynne RD, Hampton JR. The effects of BTS 49465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers. J Hypertens 1984;2(suppl 3):547-549
116. Kessler PD, Packer M. Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. Am Heart J 1987; 113:137-143
117. Gottlieb SS, Krekin ML, Medina N, et al. Sustained hemodynamic response to flosequinan in patients with chronic heart failure receiving converting-enzyme inhibitors (abstract). Circulation 1991;84(suppl II):II-241
118. Cowley AJ. Clinical efficacy of flosequinan in heart failure. Am Heart J 1991;121:983-988
119. Schneeweiss A, Wynne RD, Marmor A. Effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction. Crit Care Med 1989;17: 879-881
120. Hass GJ, Binkley PF, Carpenter JA, Leier CV. Central and regional hemodynamic effects of flosequinan for congestive heart failure. Am J Cardiol 1989;63:1354-1359
121. Dubois-Rande JL, Loisance D, Duval AM, et al. Enoximone, a pharmacological bridge to transplantation. Br J Clin Pract 1988;(suppl 64):73-79
122. Dec GW, Fifer MA, Herrman HC, et al. Long-term outcome of enoximone therapy in patients with refractory heart failure. Am Heart J 1993;125:423-429
123. Roth SNL, Moe G. Intermittent intravenous amrinone infusion: a potentially cost effective mode of treatment of patients with refractory heart failure. Can J Cardiol 1993; 9:231-237
124. Roffman DS, Applefield MM, Grove WR, et al. Intermittent dobutamine hydrochloride infusions in outpatients with chronic congestive heart failure. Clin Pharm 1985;4 :195-199
125. Miller LW, Merkle EJ, Herrmann V. Outpatient dobutamine for end-stage congestive heart failure. Crit Care Med 1990; 18:S30-S33
126. Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared to placebo. Circulation 1990;82:774-780
127. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475
128. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and on angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Circulation 1993;88:492-450
129. Massie B, Bourassa M, DiBianco R, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in multicenter-controlled trial. Circulation 1985;71:963-971
130. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6
131. Stevenson LW, Warner SL, Hamilton MA, et al. Modeling distribution of donor hearts to maximize early candidate survival. Circulation 1992;86(suppl II):II-224-II-230
132. Deeb GM, Bolling SF. The role of amrinone in potential heart transplant patients with pulmonary hypertension. J Cardiothorac Anesth 1989;3(suppl 2):33-37
133. O'Connell JB, Gilbert EM, Renlund DG, Bristow MR. Enoximone as a bridge to heart transplantation: the Utah experience. J Heart Lung Transplant 1991;10:477-481
134. Dreyfus G, Arby B, Jebara V, et al. Enoximone as alternative to mechanical support while awaiting cardiac transplantation. Lancet 1989;1:153
135. Binkley PF, Starling RC, Hammer DF, Leier CV. Usefulness of hydralazine to withdraw from dobutamine in severe congestive heart failure. Am J Cardiol 1991;68:1103-1106
136. Walsh WF, Greenberg BH. Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 1981;64:499-505
137. Cohn JN, Burke LP. Nitroprusside. Ann Intern Med 1979; 91:752-757
138. Page IH, Corcoran AC, Dustain HP, Koppanyi T. Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. Circulation 1955;11:188-198
139. Verhaeghe RH, Shepherd JT. Effect of nitroprusside on smooth muscle and adrenergic nerve terminals in isolated blood vessels. J Pharmacol Exp Ther 1976;199:269-277
140. Cohn JN, Rodriquera E, Guiha NH. Left ventricular function in hypertensive heart disease. In: Onesti G, Kim KE, eds. Hypertension. Mechanisms and management. New York: Grune and Stratton, 1973:191-197
141. Guiha NH, Cohn JN, Mikulic E, et al. Treatment of refractory-heart failure with infusion of nitroprusside. N Engl J Med 1974;291:587-592
142. Cohn JN, Taylor N, Vrobei T, Moskowitz R. Contrasting effect of vasodilators on heart rate and plasma catecholamines in patients with hypertension and heart failure (abstract). Clin Res 1978;26:547A
143. Abrams J. Nitrates. In: Parmley WW, Chatterjee K, eds. Cardiology, vol 1. Philadelphia: J.B. Lippincott, 1994:1-21
144. Cody RJ, Pickworth KK. Approaches to diuretic therapy and electrolyte imbalance in congestive heart failure. In: Deedwania PC, ed. Cardiology clinics. Congestive heart failure: state of the art. Philadelphia: W.B. Saunders, 1994:37-50
145. Vasko MR, Broun-Cartwright D, Knochel PA, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985;102:314-318.
146. Lahov M, Rege VA, Ra'Anoni P, Theodor E. Intermittent administration of furosemide vs. continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992;102:725-731
147. Van Meyel JJM, Smits P, Dormans T, et al. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med 1994;235:329-334
148. Motwani JG, Fenwick MK, Morton JJ, Struthers AD. Furosemide-induced natriuresis is augmented by ultra low dose captopril but not by standard doses of captopril in chronic heart failure. Circulation 1992;86:439-445
149. Graziani G, Cantaluppi A, Casati S, et al. Dopamine and furosemide in oliguric acute renal failure. Nephron 1984; 37:39-42
150. Duke GJ, Bersten AD. Dopamine and renal salvage in the critically ill patients. Anesth Intensive Care 1992;20:277-302
151. Schnermann J, Todd KM, Briggs JP. Effect of dopamine on the tubuloglomerular feedback mechanism. Am J Physiol 1990;258:F790-F798
152. Lindner F. Synergism of dopamine and furosemide in diuretic-resistant, oliguric acute renal failure. Nephron 1983;33:121-126
153. Magrini F, Foulds R, Roberts N, et al. Renal hemodynamic effects of dopexamine hydrochloride. Am J Cardiol 1988;62:53C-56C
154. Jamison M, Widerhorn J, Weber L, et al. Central and renal hemodynamic effects of a new agonist at peripheral dopamine - and beta-2 adrenoreceptors (dopexamine) in patients with heart failure. Am Heart J 1989;117:607-614
155. De Marco T, Kwasman M, Lau D, Chatterjee K. Dopexamine hydrochloride in chronic congestive heart failure with improved cardiac performance without increased metabolic cost. Am J Cardiol 1988;62:57C-62C
156. Warren JV, Stead EA. Fluid dynamics in chronic congestive heart failure. Arch Intern Med 1944;73:138-147
157. Merrill AJ. Edema and decreased renal blood flow in patients with chronic congestive heart failure: evidence of "forward failure" as the primary cause of edema. J Clin Invest 1946;25:389-460
158. Agnostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med 1994;96:191-199
159. Cipolla CM, Grazi S, Rimondini A, et al. Changes in circulating norepinephrine with hemofiltration in advanced congestive heart failure. Am J Cardiol 1990;66:987-994
160. Akiba T, Taniquchi K, Marumo F, Matsuda O. Clinical significance of renal hemodynamics in severe congestive heart failure: responsiveness to ultrafiltration therapies. Jpn Cir J 1989;53:191-196
161. Lauer A, Saccaggi A, Ronco C, et al. Continuous arteriovenous hemofiltration in the critically ill patient. Clinical use and operational characteristics. Ann Intern Med 1983; 99:455-460
162. Simpson IA, Rae AP, Simpson K, et al. Ultrafiltration in the management of refractory congestive heart failure. Br Heart J 1986;55:344-347
163. Chatterjee K. Amiodarone in chronic heart failure. J Am Coll Cardiol 1989;14:1775-1776
164. Chakko CS, Gheorghiade M. Ventricular arrhythmias in severe heart failure: incidence, significance and effectiveness of antiarrhythmic therapy. Am Heart J 1985;109:497-504
165. Dargie HJ, Cleland JGF, Leckie BJ, et al. Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation 1987;76(suppl IV):IV-98-IV-107
166. Gradman A, Deedwania P, Cody R, for the Captopril-Digoxin Study Group. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol 1989;14:564-570
167. Holmes J, Kubo SH, Cody RJ, Kligfield P. Arrhythmias in ischemic and non-ischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. Am J Cardiol 1985;55:146-151
168. Nademanee K. The amiodarone odyssey. J Am Coll Cardiol 1992;20:1063-1065
169. Hine L, Laird N, Hewitt P, Chalmers TC. Meta-analysis of empirical chronic antiarrhythmic therapy after myocardial infarction. JAMA 1989;262:3037-3040
170. Nattel S, Talajic M, Fermini B, Roy D. Amiodarone: pharmacology, clinical actions, and relationship between them. J Cardiovasc Electrophysiol 1992;3:266-280
171. Singh BN, Courtney KE. The classification of antiarrhythmic mechanism of drug action: experimental and clinical considerations. In: Zipes DP, Jalife J, eds. Cardiac electrophysiology. From cell to bedside. Philadelphia: W.B. Saunders, 1990:882-897
172. Nademanee K, Piwonka RW, Singh BN, Hershman JM. Amiodarone and thyroid function. Prog Cardiovasc Dis 1989;31:427-437
173. Shaikh NA, Dounar E, Butany J. Amiodarone - an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquin, and chlorpromazine. Mol Cell Biochem 1987;76:163-172
174. Haworth RA, Goknur AB, Berkoff HA. Inhibition of ATP-sensitive potassium channels of adult rate heart cells by antiarrhythmic drugs. Circulation 1989;65:1157-1160
175. Ceremuzynski L, Kleczar E, Kreminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-1062
176. Teo K, Yusuf S, Furberg C. Overview of randomized trials of low-dose amiodarone on mortality in cardiac patients. Circulation 1992;86(suppl I):I-534
177. Kiowski W, Pfisteres M, Bunner H, et al. Long-term effect of one year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation 1992;86(suppl I):I-534
178. Cleland JGJ, Dargie HJ, Findlay JN, Wilson JT. Clinical hemodynamic, and antiarrhythmic effects of long-term treatment with amiodarone of patients in heart failure. Br Heart J 1987;57:436-445
179. Galli FC, De Marco T, Chatterjee K. Does amiodarone improve survival of patients with refractory heart failure due to dilated cardiomyopathy (abstract). Clin Res 1994;42:38A
180. Neri R, Mestroni L, Salvi A, et al. Ventricular arrhythmias in dilated cardiomyopathy: efficacy of amiodarone. Am Heart J 1987;113:707-715
181. Hamer AWR, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989; 14:1768-1774
182. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991;122: 1016-1021
183. Doval HC, Nul DR, Grancelli HO, et al. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498
184. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and symptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82
185. Mason JW. Amiodarone. N Engl J Med 1987;16:455-466
186. Nademanee K, Singh BN, Hendrickson JA, et al. Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Int Med 1983;98:577-584
187. Chelimsky-Fallick C, Middlekauff HR, Stevenson WG, et al. Amiodarone therapy does not compromise subsequent heart transplantation. J Am Coll Cardiol 1992;2:1556-1561
188. Mirowski M. The automatic implantable cardioverter-defibrillator: an overview. J Am Coll Cardiol 1985;6:461-466
189. Mercando AD, Furman S, Johnston D, et al. Survival of patients with automatic implantable cardioverter-defibrillator. Prog Am Coll Electrophysiol 1988;11:2059-2063
190. Tchou PJ, Kadri N, Anderson J, et al. Automatic implantable cardioverter-defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med 1988;109:529-534
191. Bolling SF, Deeb M, Morady F, et al. Automatic internal cardioverter-defibrillator: a bridge to heart transplantation. J Heart Lung Transplant 1991;10:562-566
192. Jeevanandam V, Bielefeld MR, Auteri JS, et al. The implantable defibrillator: an electronic bridge to cardiac transplantation. Circulation 1992;86(suppl II):II-276-II-279
193. Bardy GH, Hofer B, Johnson G, et al. Implantable transvenous cardioverter-defibrillators. Circulation 1993;87: 1152-1168
194. Braunwald E, Frye RL, Aygen MM. Studies on Starling's law of the heart: III. Observations in patients with mitral stenosis and atrial fibrillation on relationships between left ventricular end-diastolic segment length, filling pressure, and the characteristics of ventricular contraction. J Clin Invest 1960;39:1874-1884
195. Dristas A, Ciaramella F, Oakley C, Nihoyannopoulos P. Beat-to-beat hemodynamics during atrial fibrillation: observations in normal and impaired left ventricular function. J Am Coll Cardiol 1994;23:416A
196. Naito M, Daniel D, Michelson EL, et al. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983;106:284-291
197. Grogan M, Smith HC, Gersh B, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573
198. Phillips E, Levine SA. Auricular fibrillation without other evidence of heart disease: a cause of reversible heart failure. Am J Med 1949;7:478-489
199. Tamita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation 1991; 83:635-644
200. Spinale FG, Tanaka R, Crawford FA. Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation 1992; 85:717-729
201. Lundestran T, Ryden L. Chronic atrial fibrillation: long-term results of direct current cardioversion. Acta Scand Med 1988;223:53-59
202. Dunn M, Alexander J, de Silva R, Hildner F. Antithrombotic therapy in atrial fibrillation. Chest 1989;95(suppl I): 118s-127s
203. Henry WL, Morganroth J, Pearlman AS, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976;53:273-279
204. Dittrich HC, Erickson JS, Schneiderman T, et al. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989;63: 193-197
205. Kieny JR, Sacrez A, Facello A, et al. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1290-1295
206. Halpern SW, Ellrodt G, Singh BN, Mandel WJ. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation to left atrial size. Br Heart J 1980;44:589-595
207. Fenster PE, Comess KA, Marsh R, et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983;106:501-504
208. Borgeat A, Goy JJ, Maendly R, et al. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986;58:496-498
209. Nathan AW, Camm AJ, Bexton RS, Hellestrand KJ. Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias. Clin Cardiol 1987;10:317-322
210. Rotmensch HH, Belhassen B. Amiodarone in the management of cardiac arrhythmias: current concepts. Med Clin North Am 1988;72:321-358
211. Van Gelder IC, Crijns HG, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993;72:560-566
212. Markiewicz W, Winkle R, Binetti G, et al. Normal myocardial contractile state in the presence of quinidine. Circulation 1976;53:101-106
213. Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients: findings based on the Boston collaborative drug surveillance program. Prog Cardiovasc Dis 1977;12:151-163
214. Copelan SE, Antonin AA, Bernard SA. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990;82:1106-1116
215. Anderson JL, Gilbert EM, Alpert RL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;180:1557-1570
216. Echt DS, Liebson PR, Mitchell LH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781-788
217. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989;111:107-111
218. Muhiddin KA, Turner P, Blackett P. Effect of flecainide on cardiac output. Clin Pharm Ther 1985;37:260-263
219. Josephson MA, Kaul S, Hopkins J, et al. Hemodynamic effects of intravenous flecainide relative to the level or ventricular function in patients with coronary artery disease. Am Heart J 1985;109:41-45
220. Flaker CG, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532
221. McKibbin JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalemia, syncope and torsade de pointes. Br Heart J 1984; 51:157-162
222. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. Circulation 1990;82:1932-1939
223. Lynch JJ, Wilber DJ, Montgomery DG, et al. Antiarrhythmic and antifibrillatory actions of the levo- and dextro-rotatory isomers of sotalol. J Cardiovasc Pharm 1984;6:1132-1141
224. Trobaugh GB, Kudenchuck PJ, Greene HL, et al. Effects of amiodarone on ventricular function as measured by gated radionuclide angiography. Am J Cardiol 1984;54: 1263-1266
225. Gosselink AT, Crijns HJ, van Gelder IC, et al. Low dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267: 3289-3293
226. Landymore R, Marble A, Mackinnon G, et al. Effects of oral amiodarone on ventricular function in dogs: clinical implications for patients with life-threatening ventricular arrhythmias. Ann Thorac Surg 1984;37:141-146
227. Rawles JM. What is meant by "controlled" ventricular rate in atrial fibrillation. Br Heart J 1990;63:157-161
228. Smith TW. Digitalis: mechanisms of action and clinical use. N Engl J Med 1988;318:358-365
229. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of atrial fibrillation: the effect of digoxin. Br Heart J 1990;63:225-227
230. Klein HO, Kaplinsky E. Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction. Am J Cardiol 1982;50:894-902
231. DiBianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984;108:1121-1127
232. Sarter BH, Marchlinski FF. Redefining the role of digoxin in the treatment of atrial fibrillation. Am J Cardiol 1992;69:71G-81G
233. Singh HN, Vaughan O, Williams EM. A fourth class of antidysrhythmic action? Effect of verapamil on oubain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res 1972;6:109-119
234. Scheinman MM, Morally F, Hess DS, Gonzalez R. Catheter-induced ablation of the atrioventricular junction to control refractory supra-ventricular arrhythmias. JAMA 1982;248: 851-855
235. Gallagher JJ, Svenson RH, Kasell JH, et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system. N Engl J Med 1982;306:194-200
236. Huang SK, Bharati S, Graham AR, et al. Closed-chest catheter desiccation of the atrio-ventricular junction using radiofrequency energy - a new method of catheter ablation. J Am Coll Cardiol 1987;9:349-358
237. Evans GT Jr, Scheinman MM, Bardy G, et al. Predictors of in-hospital mortality after DC catheter ablation of atrioventricular junction: results of a prospective, international, multicenter study. Circulation 1991;84:1924-1937
238. Olgin JE, Scheinman MM. Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol 1993;21:557-564
239. Langberg JJ, Chin MC, Rosenqvist M, et al. Catheter ablation of the atrioventricular junction with radiofrequency energy. Circulation 1989;80:1527-1535
240. Morally F, Calkins H, Langberg JJ, et al. A prospective randomized comparison of direct current and radiofrequency ablation of the atrioventricular junction. J Am Coll Cardiol 1993;21:102-109
241. Langberg JJ, Chin MC, Schamp DJ, et al. Ablation of the atrioventricular junction with radiofrequency using a new electrode catheter. Am J Cardiol 1991;67:142-147
242. Yeung Lai Wah JA, Alison JF, Lonergan L, et al. High success rate of atrioventricular node ablation with radiofrequency energy. J Am Coll Cardiol 1991;18:1753-1758
243. Jackman WM, Wang X, Friday KJ, et al. Catheter ablation of the atrioventricular junction using radiofrequency current in 17 patients: comparison of standard and large tip catheter electrodes. Circulation 1991;83:1562-1576
244. Evans GT, Scheinman MM, the Executive Committee of the Registry. The percutaneous cardiac mapping and ablation registry: summary of results. PACE 1987;10:1395-1399
245. Levy S, Bru P, Aliot E, et al. Long-term follow-up of atrioventricular junctional transcatheter electrical ablation. PACE 1988;11:1149-1153
246. Jordaens L, Rubben L, Vertongen P. Sudden death and long-term survival after ablation of the atrioventricular junction. Eur J Cardiac Pacing and Electrophysiology 1993;3:232-237
247. Windecker J, Plumb VJ, Epstein AJ, Kay GN. Does AV nodal ablation impair long-term survival compared with medical treatment of atrial fibrillation? J Am Coll Cardiol 1994;23:84A
248. Williamson BD, Man KC, Daoud E, et al. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994;331:910-917
249. Packer DL, Hardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986;57:563-570
250. Lemery R, Brugada P, Cheriex E, Wellens HJ. Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest ablation of the atrioventricular junction for atrial fibrillation. Am J Cardiol 1987;60:1406-1408
251. Rosenqvist M, Lee MA, Moulinier L, et al. Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction. J Am Coll Cardiol 1990; 16:1467-1474
252. Heinz G, Siostrzonek P, Kreiner G, Gössinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol 1992;69:489-492
253. Fitzpatrick AP, Kourouyan HD, Siu A, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation. J Am Coll Cardiol 1994;23:350A
254. Rodriguez LM, Smeets JL, Xie B, et al. Improvement in left ventricular function by ablation of atrioventricular conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993;72:1137-1141
255. Zile MR, Blaustein AS, Shimuzu G, Gaasch WH. Right ventricular pacing reduces the rate of left ventricular relaxation and filling. J Am Coll Cardiol 1987;10:702-709
256. Tanabe A, Mohri T, Ohga M, et al. The effects of pacing-induced left bundle branch block on left ventricular systolic and diastolic performance. Jpn Heart J 1990;31:309-317
257. Askenazi J, Alexander JH, Koenigsberg DI, et al. Alteration of left ventricular performance by left bundle branch block simulated with atrioventricular sequential pacing. Am J Cardiol 1984;53:99-104
258. Rutishauser W, Wirz P, Gander M, Luthy E. Atriogenic diastolic reflux in patients with atrioventricular block. Circulation 1966;34:807-817
259. Rokey R, Murphy DJ, Nielsen AP, et al. Detection of diastolic atrioventricular valvular regurgitation by pulsed doppler echocardiography and its association with complete heart block. Am J Cardiol 1986;57:692-694
260. Panidis IP, Ross J, Munley B, et al. Diastolic mitral regurgitation in patients with atrioventricular conduction abnormalities: a common finding by Doppler echocardiography. J Am Coll Cardiol 1986;7:768-774
261. Schnittger I, Appleton CP, Hatle LK, Popp RL. Diastolic mitral and tricuspid regurgitation by Doppler echocardiography in patients with atrioventricular block: new insight into the mechanism of atrioventricular closure. Am J Coll Cardiol 1988;11:83-88
262. Ng KSK, Gibson DG. Impairment of diastolic function by shortened filling period in severe left ventricular disease. Br Heart J 1989;62:246-252
263. Hochleitner M, Hortnagl H, Hortnagl H, et al. Long-term efficacy of physiologic dual-chamber pacing in the treatment of end-stage idiopathic dilated cardiomyopathy. Am J Cardiol 1992;70:1320-1325
264. Hochleitner M, Hortnagl H, Ng C-K, et al. Usefulness of physiologic dual-chamber pacing in drug-resistant idiopathic dilated cardiomyopathy. Am J Cardiol 1990;66: 198-202
265. Kataoka H. Hemodynamic effect of physiological dual chamber pacing in a patient with end-stage dilated cardiomyopathy: a case report. PACE 1991;14:1330-1335
266. Iskandrian AS. Pacemaker therapy in congestive heart failure. Am J Cardiol 1990;66:223-224
267. von Bibra H, Wirtzfeld A, Hall R, et al. Mitral valve closure and left ventricular filling time in patients with VDD pacemakers. Assessment of the onset of left ventricular systole and the end of diastole. Br Heart J 1986;55:355-363
268. Ishikawa T, Kimura K, Nihei T, et al. Relationship between diastolic mitral regurgitation and PQ intervals or cardiac function in patients implanted with DDD pacemakers. PACE 1991;14:1797-1802
269. Brecker SJD, Xiao HO, Sparrow J, Gibson DG. Effects of dual-chamber pacing with short atrioventricular delay in dilated cardiomyopathy. Lancet 1992;340:1308-1312
270. DiCarlo LA Jr, Morady F, Krol RB, et al. The hemodynamic effects of ventricular pacing with and without atrioventricular synchrony in patients with normal and diminished left ventricular function. Am Heart J 1987;114:746-752
271. Reiter MJ, Hindman MC. Hemodynamic effects of acute atrioventricular sequential pacing in patients with left ventricular dysfunction. Am J Cardiol 1982;49:687-692
272. Sacher HL, Sacher ML. Hemodynamic benefits of atrial ventricular sequential pacing in complete heart block and left ventricular failure: case study. Angiology 1989;40: 489-495
273. Nishimura RP, Hayes DL, Holmes DR Jr, Tajik AJ. Mechanism of hemodynamic improvement by dual-chamber pacing for severe left ventricular dysfunction: an acute Doppler and catheterization hemodynamic study. J Am Coll Cardiol 1995;25:281-288
274. Alpert MA, Curtis JJ, Sanfelippo JF, et al. Comparative survival after permanent ventricular and dual chamber pacing for patients with chronic high-degree atrioventricular block with and without pre-existent congestive heart failure. J Am Coll Cardiol 1986;7:925-932
275. Alpert MA, Curtis JJ, Sanfelippo JF, et al. Comparative survival after permanent ventricular and dual-chamber pacing for patients with chronic symptomatic sinus node dysfunction with and without congestive heart failure. Am Heart J 1987;113:958-965
276. Eichhorn RJ. The paradox of β-adrenergic blockade for the management of congestive heart failure. Am J Med 1992;92:527-538
277. Packer M, Lee WH, Kessler PD, et al. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987;75(suppl IV): IV80-IV92
278. Reichenbach DD, Benditt EP. Catecholamines and cardiomyopathy: the pathogenesis and potential importance of myofibrillar degeneration. Hum Pathol 1970;1:125-149
279. Haft JI. Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis 1974;17:73-85
280. 1-receptor down-regulation or heart failure. Circ Res 1986;59:297-309
281. Bristow MR, Port JD, Sandoval AB, et al. β-adrenergic receptor pathways in the failing human heart. Heart Failure 1989;5:77-90
282. Colucci WS, Alexander RW, Williams GH, et al. Decreased lymphocyte beta-adrenergic receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med 1981;305:185-190
283. Fowler MB, Laser JA, Hopkins GL, et al. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986;74:1290-1302
284. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205-211
285. Terce MA, Jessup M. β-adrenergic blockade in patients with chronic heart failure: issues and answers. Primary Cardiol 1994;20:33-38
286. Heilbrunn S, Shah P, Bristow M, et al. Increased β-receptor density and improved response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-490
287. 1-adrenergic receptor up regulation? Circulation 1984;70(suppl 2): 112-116
288. Eichhorn EJ, Bedotto J, Malloy CR, et al. Effect of β-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1989;82:473-483
289. Andersson B, Blomstrom-Lundqvist C, Hedner T, Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol 1991;18:1059-1066
290. Leung WH, Lau CP, Wong CK, et al. Improvement in exercise performance and hemodynamics by labetolol in patients with idiopathic dilated cardiomyopathy. Am Heart J 1990;119:884-890
291. Nemanich JW, Veith RC, Abrass JB, Stratton JR. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 1990;66:843-848
292. Waagstein F, Caidahl K, Wallentin I, et al. Long-term beta blockade in dilated cardiomyopathy. Circulation 1989; 80:551-563
293. Engelmeier RS, O'Connell JB, Walsh RW, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72: 536-546
294. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-475
295. Gilbert EM, Anderson JL, Dietchman D, et al. Chronic β-blocker-vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-229
296. Pollock SG, Lytash J, Tedesco C, et al. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990;66: 603-607
297. Woodley SL, Gilbert EM, Anderson JL, et al. β-blockade with bucindolol in heart failure due to ischemic vs. idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441
298. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980;44:134-142
299. Currie PJ, Kelly MJ, McKenzie A, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984;3:203-209
300. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either dilated or ischemic cardiomyopathy. Circulation 1994;89(4):1632-42
301. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036
302. McAlpine HM, Henderson F, Dargie H. Addition of xamoterol to captopril in severe chronic heart failure. Eur J Clin Pharmacol 1989;36:A71
303. Dasgupta P, Broodhurst P, Raftery EB, Lahiri A. Value of carvediol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:1118-1123
304. Wisenbaugh T, Katz I, Davis J. Long-term (3 month) effects of nevivolol on cardiac performance in patients with dilated cardiomyopathy. Circulation 1992;86(suppl I):I-645
305. Chatterjee K. Potential use of third-generation β-blockers in heart failure. J Cardiovasc Pharmacol 1989;14(suppl 7): S22-S27
306. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979;1:1374-1376
307. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510
308. Kennedy HL, Barker A, Brooks MM, et al. Beta-blocker therapy and mortality in the cardiac arrhythmia suppression trial (CAST), (abstract). Circulation 1992;86(suppl I):I-403
309. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1142-1146
310. Lijnen PI, Amery AK, Fagard RH, et al. The effects of beta-adrenoreceptor blockade on renin, angiotensin, aldosterone, and catecholamines at rest and during exercise. Br J Pharmacol 1979;7:175-181
311. Olsson G, Daleskog M, Hjemdahl P, Rehnqvist N. Unchanged peripheral sympathetic activity following withdrawal of chronic metoprolol treatment. A study of noradrenaline concentrations and kinetics in plasma. Br J Clin Pharmacol 1984;18:573-579
312. Reedy JE, Pennington G, Miller LW, et al. Status I heart transplant patients: conventional versus ventricular assist device support. J Heart Lung Transplant 1992;11:247-252
313. Marks JD, Karwande SV, Richenbacker WE, et al. Perioperative mechanical circulatory support for transplantation. J Heart Lung Transplant 1992;11:117-128
314. Birovljev S, Radovancevic B, Burnett CM, et al. Heart transplantation after mechanical circulatory support: four years experience. J Heart Lung Transplant 1992;11:240-245
315. Pifarre R, Sullivan H, Montoya A, et al. Comparison of results after heart transplantation: mechanically supported versus non-supported patients. J Heart Lung Transplant 1992;11:235-239
316. Lazar JM, Ziady GM, Dummer SJ, et al. Outcome and complications of prolonged intra-aortic balloon counterpulsation in cardiac patients. Am J Cardiol 1992;69:955-958
317. Gottlieb SO, Brinker JA, Borkon AM, et al. Identification of patients at high risk for complications of intra-aortic balloon counterpulsation: a multivariate risk factor analysis. Am J Cardiol 1984;53:1135-1139
318. Goldman BS, Hill TJ, Rosenthal GA, et al. Complications associated with use of the intra-aortic balloon pump. Can J Surg 1982;25:153-156
319. Harvey JC, Goldstein JE, McCabe JC. Complications of percutaneous intra-aortic balloon pumping. Circulation 1981;64(suppl II):II-114-II-117
320. Pennington DG, Swartz M, Codd JE, et al. Intra-aortic balloon pumping in cardiac surgical patients. A nine year experience. Ann Thorac Surg 1983;35:125-131
321. Martin RS III, Moncure AC, Buckley MJ, et al. Complications of percutaneous intra-aortic balloon insertion. J Thorac Cardiovasc Surg 1983;85:186-190
322. Karl TR, Sano S, Horton S, Mie RBB. Centrifugal pump left heart assist in pediatric cardiac operations: indications, technique, and results. J Thorac Cardiovasc Surg 1991; 102:624-630
323. Golding LAR, Stewart RW, Sinkewich M, et al. Nonpulsatile ventricular assist bridging to transplantation. Trans Am Soc Artif Intern Organs 1988;34:476-479
324. Joyce LD, Kiser JC, Eales F, et al. Experience with the Sarns centrifugal pump as a ventricular assist device. Trans Am Soc Artif Intern Organs 1990;30:M619-M623
325. Noon GP. Bio-medicus ventricular assistance. Ann Thorac Surg 1991;52:180-181
326. Mickleborough LL, Rebeyka I, Wilson GJ, et al. Comparison of left ventricular assist and intra-aortic balloon counterpulsation during early reperfusion after ischemic arrest of the heart. J Thorac Cardiovasc Surg 1987;93:597-608
327. Nakatani T, Radovancevic B, Frazier OH. Right heart assist for acute right ventricular failure after orthotopic heart transplantation. Trans Am Soc Artif Intern Organs 1987; 33:695-698
328. Partner PM, Oyer PE, Pennington DG, et al. Implantable electrical left ventricular assist system: bridge to cardiac transplantation and the future. Ann Thorac Surg 1989; 47:142-150
329. Gallagher RC, Kormos RL, Gasior T, et al. Univentricular support results in reduction of pulmonary resistance and improved right ventricular function. Trans Ann Soc Artif Intern Organs 1991;37:M287-M288
330. Frazier OH, Duncan JM, Radovancevic B, et al. Successful bridge to transplantation with a new left ventricular assist device. J Heart Lung Transplant 1992;11:530-537
331. Lowe JE, Anstadt MP, Van Tright P, et al. First successful bridge to cardiac transplantation using direct mechanical ventricular actuation. Ann Thorac Surg 1991;52:1237-1245
332. Cabrol C, Solis E, Muneretto C, et al. Orthotopic transplantation of a Jarvik 7 total artificial heart. J Thorac Cardiovasc Surg 1989;97:342-350
333. Johnson KF, Prieto M, Joyce LD, et al. Summary of the clinical use of the Symbion total artificial heart: a registry report. J Heart Lung Transplant 1992;11:103-116
334. Griffith BP, Konnos RL, Hardesty RL, et al. The artificial heart: infection-related morbidity and its effect on transplantation. Ann Thorac Surg 1988;45:409-414
335. Hetzer R, Hennig E, Schiessler A, et al. Mechanical circulatory support and heart transplantation. J Heart Lung Transplant 1992;11:S175-S181
336. Levinson MM, Copeland JG. Technical aspects of total artificial heart implantation for temporary applications. J Cardiac Surg 1987;2:3-19
337. DeVries WC. The permanent artificial heart: four case reports. JAMA 1988;259:849-859
338. Moritz A, Rokitansky A, Schima H, et al. Mechanical bridge to transplantation with the Vienna heart in TAH and LVAD configuration. Int J Artif Organs 1992;15:147-150
339. Schiedermayer DL, Shapiro RS. The artificial heart as a bridge to transplant: ethical and legal issues at the bedside. J Heart Transplant 1989;8:471-473
340. Oaks TE, Pae WE Jr, Miller CA, Pierce WS. Combined registry for the clinical use of mechanical ventricular assist pumps and the total artificial heart in conjunction with heart transplantation: fifth official report - 1990. J Heart Lung Transplant 1991;10:622-625
341. Kirklin JW, Akins CW, Blackstere FH, et al. Guidelines and indications for coronary artery bypass graft surgery. A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on coronary artery bypass graft surgery). J Am Coll Cardiol 1991;17:543-589
342. Louie HW, Laks H, Milgalter E, et al. Ischemic cardiomyopathy. Criteria for coronary revascularization and cardiac transplantation. Circulation 1991;84(suppl III):III-290-III-295
343. Bounois EP, Mark DB, Pollock BG, et al. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation 1988;78(suppl I):I-151-I-157
344. Wechsler AS, Junod FL. Coronary bypass grafting in patients with chronic congestive heart failure. Circulation 1989; 79(suppl I):I-92-I-96
345. Hooper TL, Stephenson LW. Cardiomyoplasty for end-stage heart failure. Surg Annu 1993;25:157-173
346. Bocchi EA, Moreira LFP, de Moraes AV, et al. Effects of dynamic cardiomyoplasty on regional wall motion, ejection fraction, and geometry of left ventricule. Circulation 1992: 86(suppl II):II-213-II-235
347. Grandjean PA, Auston L, Chan S, et al. Dynamic cardiomyoplasty: clinical follow-up and results. J Cardiac Surg 1991;6(suppl):80-88
348. Jatene AD, Moreira LF, Stolf NAG, et al. Left ventricular function changes after cardiomyoplasty in patients with dilated cardiomyopathy. J Thorac Cardiovasc Surg 1991; 102:132-139
349. Moreira LFP, Stolf NAG, Bocchi EA, et al. Latissimus dorsi cardiomyoplasty in the treatment of patients with dilated cardiomyopathy. Circulation 1990;82(suppl IV):IV-257-IV-263
350. Bocchi EA, Moreira LFP, Belloti G, et al. Hemodynamic study during upright isotonic exercise before and six months after dynamic cardiomyoplasty for idiopathic dilated cardiomyopathy or Chagas' disease. Am J Cardiol 1991;67:213-214
351. Chachques JC, Grandjean PA, Carpentier A. Patient management and clinical follow-up after cardiomyoplasty. J Cardiac Surg 1991;6:89-99
352. Delahaye F, Jegaden O, Montagna P, et al. Latissimus dorsi cardiomyoplasty in severe congestive heart failure: the Lyon experience. J Cardiac Surg 1991;6:106-112
353. Magovern GJ, Christlieb IY, Kao RL. The Allegheny Hospital experience. In: Carpentier A, Chachques JC, Grandjean P, eds. Cardiomyoplasty. Mount Kisco, NY: Futura, 1991: 159-170
354. Lee KF, Dignan RJ, Parmar J, et al. Effects of dynamic cardiomyoplasty on left ventricular performance and myocardial mechanics in dilated cardiomyopathy. J Thorac Cardiovasc Surg 1991;102:124-131
355. Hosenpud JD, Novick RJ, Breen TJ, Daily OP. The registry of the International Society for Heart and Lung Transplantation: eleventh official report - 1994. J Heart Lung Transplant 1994;13:561-570
356. Stevenson LW. Selection and management of candidates for cardiac transplantation. In: Parmley WW, Chatterjee K, eds. Cardiology. Philadelphia: J.B. Lippincott, 1994:1-13